Subclinical hypothyroidism in older individuals

Area of Science:

• Endocrinology
• Geriatrics
• Internal Medicine

Background:

• Subclinical hypothyroidism (SCH), defined by elevated thyroid-stimulating hormone (TSH) with normal free thyroxine, is common in older adults.
• Management guidelines for SCH in the elderly vary internationally.
• This review focuses on the clinical significance and treatment of SCH in individuals aged 65 years and older.

Purpose of the Study:

• To review current evidence on the clinical impact of SCH in older individuals.
• To evaluate the efficacy of levothyroxine treatment for SCH in this age group.
• To provide evidence-based recommendations for managing SCH in older adults.

Main Methods:

• Narrative review of published data from the past decade.
• Inclusion of meta-analyses, randomized clinical trials, and cohort studies.
• Focus on individuals aged 65 years and older with subclinical hypothyroidism.

Main Results:

• No significant increase in cardiovascular, musculoskeletal, or cognitive issues was observed in older adults with TSH levels between 4.5-7.0 mIU/L compared to euthyroid individuals.
• Levothyroxine treatment did not improve hypothyroidism symptoms, cardiac function, or bone parameters in older adults with SCH.
• Persistent TSH concentrations persistently ≥7.0 mIU/L warrant consideration for levothyroxine treatment.

Conclusions:

• Levothyroxine treatment for subclinical hypothyroidism in individuals aged 65 years and older should be considered only when TSH is persistently 7.0 mIU/L or higher.
• Initiating levothyroxine treatment for TSH levels below 7.0 mIU/L in this population is not advised based on current evidence.
• Personalized levothyroxine dosing, considering age, comorbidities, and life expectancy, is crucial.